Targeting the FAK-Src Complex in Desmoplastic Small Round Cell Tumors, Ewing Sarcoma, and Rhabdomyosarcoma

Figure 4

Cell viability and drug synergy following defactinib and dasatinib combination treatment in DSRCT, ERMS, ARMS, and ES cell lines. (a–d) Cell viability (%) following defactinib and dasatinib simultaneous, constant-ratio combination treatment in the JN-DSRCT-1 (a), RD (b), Rh30 (c), and TC32 (d) cell lines alongside the corresponding isobologram, representing the level of drug synergy. The X- and Y-axes of the isobologram represent the fraction of the portion of the drug in the combination treatment (D1 + D2) necessary to reduce an x% cell viability (D1/2) divided by the dose necessary as a single agent to generate a reduction of a similar x% cell viability (DX)1/2. D1 = defactinib, D2 = dasatinib. The line connecting the X- and Y-axes represents an additive effect (CI = 1). Points left of the line are considered a synergistic effect (CI < 1.0).

(a)

(b)

(c)

(d)